Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety - Scorecard - MDSpire
Advertisement
Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety
Clinical Scorecard: Combination of Tislelizumab, Bronchial Arterial Chemoembolization, and Systemic Chemotherapy for Advanced NSCLC with Large Tumors: Assessing Efficacy and Safety
At a Glance
Category
Detail
Condition
Advanced Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Combination of immunotherapy (tislelizumab) and bronchial arterial chemoembolization (BACE) to reduce tumor size and enhance treatment efficacy.
Target Population
Patients with advanced NSCLC (IIIB-IVB) and bulky tumors (T ≥ 50 mm).
Care Setting
Single-center retrospective analysis.
Key Highlights
Objective response rate (ORR) was significantly higher in the combination therapy group (79.41%) compared to chemotherapy alone (44.12%).
Median progression-free survival (PFS) was improved in the combination group (12.47 months) versus chemotherapy alone (7.73 months).
No significant difference in median overall survival (OS) between the two groups.
Common grade 3 or higher treatment-related adverse events included neutropenia, anemia, and thrombocytopenia.
Sequential treatment strategy and tumor diameter were identified as independent favorable predictors of PFS.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of NSCLC through pathological examination.
Management
Consider combination of tislelizumab and BACE followed by systemic chemotherapy for patients with bulky tumors.
Monitoring & Follow-up
Monitor for treatment-related adverse events, particularly hematologic toxicities.
Risks
Potential for significant adverse events including neutropenia, anemia, and thrombocytopenia.
Patient & Prescribing Data
Patients aged 18 to 75 with newly diagnosed advanced NSCLC and bulky tumors.
Sequential application of BACE may enhance the efficacy of immunotherapy and chemotherapy in bulky tumor patients.
Clinical Best Practices
Utilize a multidisciplinary tumor board for treatment decision-making.
Ensure informed consent for BACE, immunotherapy, and systemic chemotherapy.
Assess tumor anatomical suitability for BACE prior to treatment.
